CubaseBio
PrivateLast Round
Grant
Feb 17, 2026
Total Funding Raised
$2.37M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
CubaseBio operates in Healthcare & Life Sciences and is based in Stockholm. Its latest recorded funding round was a Grant round in February 2026.
CubaseBio is a biotechnology company that develops tools for 3D spatial analysis at scale, designed to accelerate drug discovery.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment, Precision Medicine
Business Model
B2B
Customer Profile
Hardware + Subscription, Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CubaseBio Comparables
Compare CubaseBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Stellaromics | 80% | |
| Resolve Biosciences | 78% | |
| 10X Genomics | 74% |
For institutional investors. Book with your work email.
CubaseBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Feb 17, 2026 | ||||
| VC Round | Feb 17, 2026 |
For institutional investors. Book with your work email.
CubaseBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Nordic Science Investments | VC Round |
| European Innovation Council Fund | Grant |
| Life Science Invest | VC Round |
| Life Science Invest | Grant |
| Voima Ventures | VC Round |
| Illumina Ventures | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 17, 2026
$4.6M round led by Nordic Science Investments and Voima Ventures.
- Feb 17, 2026
Secured $2.37M in grant funding from the European Innovation Council.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 9, 2026
Cubase Bio AB and HeartBeat.bio are launching the FACTS-3D joint research project to combine heart organoids with three-dimensional spatial transcriptomics for cardiovascular drug discovery, with approximately €1 million in Eurostars funding, in Austria on Sep 9th '26.
For institutional investors. Book with your work email.
CubaseBio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about CubaseBio's valuation, stock price, and market status.
Is CubaseBio a public or private company?
CubaseBio is a private company.
What is the current stock price of CubaseBio?
CubaseBio is a private company, so its shares have no public market price. Caplight tracks CubaseBio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is CubaseBio worth (valuation)?
Valuation information for CubaseBio is not publicly available.
Can I buy CubaseBio stock?
CubaseBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was CubaseBio's last funding round?
CubaseBio's most recent funding round was Grant on February 17, 2026.
Who are the main investors in CubaseBio?
Key investors in CubaseBio include Nordic Science Investments, Voima Ventures.
Will CubaseBio IPO soon?
No public IPO plans have been announced for CubaseBio.
How can I track CubaseBio secondary market activity?
Caplight tracks bids, offers, and trades in CubaseBio's shares on secondary markets.